Streetbeat News

TVGN

Tevogen Bio Holdings Inc.

Industry

Biotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Open

1.12

Mkt cap

205M

Volume

202K

High

1.18

P/E Ratio

3.34

52-wk high

6.25

Low

1.12

Div yield

N/A

52-wk low

0.26

Tevogen Bio, a biotech company listed on NASDAQ, is making strides in developing T cell therapeutics for infectious diseases and cancers. The company recently met with Congress to discuss its ExacTcell technology as a solution for Long COVID. Tevogen Bio has achieved significant milestones, including positive clinical trial results for its lead product, TVGN 489, and a robust intellectual property portfolio. The company is now publicly traded and included in the Russell 3000 Index.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 3:13 pm

Oracle shares surged by 8.8% in pre-market trading after reporting better-than-expected earnings and sales for Q1. Additionally, Oracle and Amazon's AWS launched Oracle Database@AWS, enhancing Oracle's cloud offerings. Other stocks like Silexion Therapeutics and Quoin Pharmaceuticals also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 10:41 am

MIRA Pharmaceuticals shares surged 44.8% in pre-market trading after announcing a successful rat study with Ketamin-2. Other notable pre-market movers include MEDIROM Healthcare, Prestige Wealth, and Tevogen Bio, among others.

Portfolio Pulse from Avi Kapoor

August 26, 2024 | 9:58 am

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) has secured a $6 million Series C Preferred Stock investment from The Patel Family, LLP. This investment will support Tevogen's development of T cell therapeutics in oncology, neurology, and virology.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 1:05 pm

Tevogen Bio Holdings (NASDAQ:TVGN) reported a Q2 EPS of $(0.04), showing a significant improvement from $(0.18) per share in the same period last year, marking a 77.78% increase.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:09 pm

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) reaffirmed that its Form S-1, declared effective by the SEC on August 2, 2024, does not involve any previously undisclosed new issuances of dilutive securities. The registration statement pertains to earnout shares, shares underlying outstanding warrants, and the resale of shares and warrants by existing securityholders.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 3:06 pm

Tevogen Bio has filed a registration statement on Form S-1 to register the issuance of previously disclosed shares of the company's common stock.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 4:49 pm

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) will join the Russell 3000 Index effective July 1, 2024, as part of the annual reconstitution of the Russell US Indexes.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 7:47 pm

The article highlights the pre-market movements of various health care stocks on Wednesday. Notable gainers include Avidity Biosciences (NASDAQ:RNA), Molecular Partners (NASDAQ:MOLN), and Longeveron (NASDAQ:LGVN). Significant losers include ThermoGenesis Holdings (NASDAQ:THMO) and Calidi Biotherapeutics (AMEX:CLDI).

Portfolio Pulse from Benzinga Insights

June 12, 2024 | 12:06 pm

Tevogen Bio Holdings shares are trading higher after the company entered an agreement for $50 million in financing.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 7:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.